Free Trial
NASDAQ:EYEN

Eyenovia Q1 2025 Earnings Report

Eyenovia logo
$2.44 -0.23 (-8.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.50 +0.06 (+2.25%)
As of 06/13/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eyenovia EPS Results

Actual EPS
-$1.59
Consensus EPS
-$7.20
Beat/Miss
Beat by +$5.61
One Year Ago EPS
N/A

Eyenovia Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$1.60 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Eyenovia Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 18, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Eyenovia's Q4 2024 earnings is scheduled for Monday, August 11, 2025

Eyenovia Earnings Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
See More Eyenovia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eyenovia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyenovia and other key companies, straight to your email.

About Eyenovia

Eyenovia (NASDAQ:EYEN), an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Eyenovia Profile

More Earnings Resources from MarketBeat